Cozart gets RapiScan vote of confidence in UK, expands overseas
This article was originally published in Clinica
Executive Summary
The pace of business for UK immunodiagnostics company Cozart Bioscience is hotting up. The Abingdon-based company is planning a worldwide launch (except US) of its sensitive on-site RapiScan test for detecting buprenorphine use and nor- buprenorphine in urine. The analgesic is used as an alternative to methadone in moving patients off heroine and opiates, and the kit will be a useful tool helping staff in drug dependency clinics to check rapidly - within ten minutes - if patients are complying with their treatment regimes. The launch will take place next month.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.